<DOC>
	<DOCNO>NCT00730080</DOCNO>
	<brief_summary>Investigators Washington University examine effect sapropterin ( Kuvan ) brain cognition individual phenylketonuria ( PKU ) use neuropsychological neuroimaging procedure . Sapropterin medication develop BioMarin Pharmaceutical Inc. approve FDA treatment patient PKU reduce phenylalanine ( Phe ) level . Patients begin treatment sapropterin standard clinical care enrol study . As first step , patient PKU receive baseline neuropsychological neuroimaging evaluation 1 day prior begin treatment sapropterin . Screening response sapropterin occur 4 week . At end 4 week , response sapropterin review . Patients reduction ≥ 20 % blood Phe ( i.e. , responder ) receive follow-up neuropsychological neuroimaging evaluation 6 month treatment sapropterin . Patients ( responder nonresponders ) receive long-term follow-up neuropsychological neuroimaging evaluation 3 5 year initial enrollment study . The focus neuropsychological test executive ability , ability particularly susceptible disruption individual PKU . We hypothesize improvement ability occur follow treatment sapropterin . For neuroimaging assessment , structural magnetic resonance imaging ( MRI ) permit evaluation change structure volume gray white matter brain , whereas diffusion tensor imaging ( DTI ) permit evaluation microstructural white matter integrity .</brief_summary>
	<brief_title>Sapropterin Individuals With Phenylketonuria</brief_title>
	<detailed_description>Investigators Washington University examine effect sapropterin ( Kuvan ) brain cognition individual phenylketonuria ( PKU ) use neuropsychological neuroimaging procedure . Sapropterin medication develop BioMarin Pharmaceutical Inc. approve FDA treatment patient PKU reduce phenylalanine ( Phe ) level . Patients begin treatment sapropterin standard clinical care enrol . As first step , patient PKU ≥ 6 year age receive baseline neuropsychological neuroimaging evaluation 1 day prior begin treatment sapropterin . Screening response sapropterin ( 20mg/kg/day ) occur 4 week standard care enrol patient . At end 4 week , response sapropterin review . Patients reduction ≥ 20 % blood Phe ( i.e. , responder ) receive follow-up neuropsychological neuroimaging evaluation 6 month treatment sapropterin . Patients ( responder nonresponders ) receive long-term follow-up neuropsychological neuroimaging evaluation 3 5 year initial enrollment study . A matched control group healthy individual without PKU receive baseline follow-up neuropsychological neuroimaging evaluation comparison purpose control possible practice effect repeat neuropsychological testing . The focus neuropsychological test executive ability , ability particularly susceptible disruption individual PKU . Specifically , focus neuropsychological assessment work memory , strategic processing , inhibitory control , research group show executive ability impaired individual PKU . ( White , D. 2001 Neuropsychol . ) ( White , D. 2002 J. Int . Neuropsychol . Soc . ) ( Christ , S. 2006 Dev . Neuropsychol . ) We hypothesize improvement ability occur follow treatment sapropterin . For neuroimaging assessment , structural magnetic resonance imaging ( MRI ) diffusion tensor imaging ( DTI ; mean diffusivity fractional anisotropy ) use . Structural MRI permit evaluation change structure volume gray white matter brain . DTI permit evaluation microstructural white matter integrity . Brain abnormality note individual PKU , use DTI research group recently identify abnormality integrity white matter early continuously treated individual PKU . The primary objective propose study two-fold . First , determine whether cognition ( particularly executive ability ) improve patient PKU treat sapropterin . Second , determine whether integrity brain improve patient PKU treat sapropterin . In addition , interrelationship change cognition brain examine .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Willing able provide inform consent assent . Willing able comply study procedure . Greater equal 6 year age . For phenylketonuria , intention physician prescribe sapropoterin . For phenylketonuria , phenylalanine level great equal 450μmol/L . For phenylketonuria , negative pregnancy test childbearing potential . For phenylketonuria , willing use contraception sexually active . Pregnant , breastfeeding , plan become pregnant study . Use investigational product le 30 day prior study . Concurrent condition could interfere participation safety . Any condition create high risk poor compliance study . Perceived unreliable unavailable study . Use LDopa , methotrexate , drug inhibit folate metabolism . For phenylketonuria , know hypersensitivity sapropterin excipients .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>phenylketonuria</keyword>
	<keyword>sapropterin</keyword>
	<keyword>Kuvan</keyword>
	<keyword>cognition</keyword>
	<keyword>executive ability</keyword>
	<keyword>brain</keyword>
</DOC>